EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects

Fundamental and Clinical Pharmacology

Volumn 23, Issue 5, 2009, Pages 617-624

  Sabbatini, Massimo ^a   Capone, Domenico ^a   Gallo, Riccardo ^a   Pisani, Antonio ^a   Polichetti, Giuliano ^a   Tarantino, Giovanni ^a   Gentile, Antonio ^a   Rotaia, Eliana ^a   Federico, Stefano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Enteric coated mychophenolic acid; Gastrointestinal symptoms; Mycophenolate mofetil; Renal transplant; Shift

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG COATING; DRUG DOSE REDUCTION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE;

DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL DISEASES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TABLETS, ENTERIC-COATED;

EID: 69949184958     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00711.x     Document Type: Article

References (31)

1. Budde K., Glander P., Diekmann F. et al. Review of the immunosuppressant enteric-coated mychophenolate sodium. Expert Opin. Pharmacother. (2004) 5 1333 1345.
2. Bjarnason I. Enteric coating of mycophenolate sodium: a rational to limit topical gastrointestinal lesions and extend the therapeutic index of mycophenolate. Transplant. Proc. (2001) 33 3238 3240.
3. Knoll G.A., MacDonald I., Khan A., Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J. Am. Soc. Nephrol. (2003) 14 2381 2386.
4. Hardinger K.L., Bennan D.C., Lowell J., Schnitzler M.A. Long term outcome of gastrointestinal complications in renal transplant patients treated with mychopenolate mofetil. Transpl. Int. (2004) 17 609 616.
5. Bunnapradist S., Lentine K.L., Burroughs T.E. et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation (2006) 82 102 107.
6. Pelletier R.P., Akin B., Henry M.L. et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin. Transplant. (2003) 17 200 205.
7. Ponticelli C., Passerini P. Gastrointestinal complications in renal transplant recipients. Transpl. Int. (2005) 18 643 650. (Pubitemid 41726826)
8. Behrend M. Adverse gastrointesinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf. (2001) 24 645 663.
9. Davies N.M., Grinyo J., Heading R., Maes B., Meier-Kriesche H.U., Oellerich M. Gastrointestinal side-effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol. Dial. Transplant. (2007) 22 2440 2448.
10. Budde K., Bauer S., Hambach P. et al. Pharmacokinetic and pharmacodynamic comparison of mycophenolate mofetil and enteric-coated mycophenolate sodium in maintenance transplant patients. Am. J. Transplant. (2007) 7 888 898.
11. Arns W., Breuer S., Choudhury S. et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin. Transplant. (2005) 19 199 206.
12. Kuypers D.R., Claes K., Evenepoel P. et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J. Clin. Pharmacol. (2003) 43 866 880.
13. Svedlund J., Sjodin I., Dotevall G. GSRS - a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig. Dis. Sci. (1988) 33 129 134.
14. Kleinman L., Kilburg A., Machnicki G. et al. Using GI-specific patient outcome measures in renal transplant patients: validation of the GSRS and GIQLI. Qual. Life Res. (2006) 15 1223 1232.
15. Laupacis A., Pus N., Muirhead N., Wong C., Ferguson B., Keown P. Disease-specific questionnaire for patients with a renal transplant. Nephron (1993) 64 226 231.
16. Jacobs R.J., Pescovitz M.D., Brook B., Birnbaum J., Dean J., Pus N. A self-administered quality of life questionnaire for renal transplant recipients. Nephron (1998) 79 123 124.
17. Laupacis A., Keown P., Pus N. et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. (1996) 50 235 242.
18. Miura M., Satoh S., Inoue K. et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther. Drug Monit. (2008) 30 46 51.
19. Salvadori M., Holzer H., de Mattos A. et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am. J. Transplant. (2004) 4 231 236.
20. Budde K., Curtis J., Knoll G. et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am. J. Transplant. (2004) 4 237 243.
21. Nashan B., Suwelack B., Ivens K. et al. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine. Transplant. Proc. (2006) 38 2856 2859.
22. Shaw L.M., Holt D.W., Oellerich M., Meiser B., van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther. Drug Monit. (2001) 23 305 315.
23. Frimat L., Cassuto-Viquier E., Charpentier B. et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. Am. J. Transplant. (2006) 6 2725 2734.
24. Le Meur Y., Buchler M., Thierry A. et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am. J. Transplant. (2007) 7 2496 2503.
25. Bremer S., Mandla R., Vethe N.T. et al. Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression. Transplantation (2008) 85 55 61.
26. Satoh S., Tada H., Murakami M. et al. Circadian pharmacokinetics of mycophenolic acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. Transplantation (2006) 82 486 493.
27. Kamar N., Oufroukhi L., Faure P. et al. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium. Nephrol. Dial. Transplant. (2005) 20 2231 2236.
28. Chan L., Mulgaonkar S., Walker R., Arns W., Ambühl P., Schiavelli R. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation (2006) 81 1290 1297.
29. Patrick D.L., Deyo R.A. Generic and disease-specific measures in assessing health status and quality of life. Med. Care (1989) 27 (3 Suppl.) 217S 232S.
30. Dumortier J., Gagnieu M.G., Salandre J. et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: a pilot study. Liver Transpl. (2006) 12 1342 1346.
31. Rosenberger J., Geckova A.M., van Dijk J.P. et al. Prevalence and characteristics of noncompliant behaviour and its risk factors in kidney transplant recipients. Transpl. Int. (2005) 18 1072 1078.